Parabilis Medicines IPO

Develops innovative peptide therapeutics to treat severe diseases through proprietary technology that creates highly tunable drug candidates.

PBLS

Buy

Buy Private Stock

Sign up to invest in private companies like Parabilis Medicines before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like Parabilis Medicines before their IPO.

Overview

Parabilis Medicines completed their IPO on June 10, 2026. Now that Parabilis Medicines is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.

Parabilis Medicines biopharmaceutical company dedicated to creating extraordinary medicines for people affected by severe diseases. They are advancing a new category of ultra-tunable peptide therapeutics called Helicon™ peptides, which are designed to overcome the limitations of current treatment options.

Sector

Healthcare & Life Sciences

Founded

2015

Headquarters

Cambridge, MA

Buy

Buy Private Stock

Sign up to invest in private companies like Parabilis Medicines before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like Parabilis Medicines before their IPO.

Parabilis Medicines Management Team

Parabilis Medicines people and management – Prior to IPO

  • CEO, President
    Mathai Mammen
  • Chief Data Science Officer
    Brandon Allgood
  • Chief Business Officer
    Greg Miller
  • Chief People Officer
    Kristen Stants

Parabilis Medicines Valuations & Financials

Looking for private company valuations and share price data?

Nasdaq Private Market Data & Intelligence is the private company valuation database covering 4,000+ venture-backed companies with daily pricing, financing history, and secondary market activity. View real-time NPM data on pre-IPO companies including valuations, private company comparable transactions, and historical share price information — the private company due diligence data sources institutional investors rely on.

Similar Companies

Explore companies

like Parabilis Medicines

  • Cerebral

    Healthcare & Life Sciences

    Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.

  • Roman Health Ventures-Logo

    Ro

    Healthcare & Life Sciences

    Healthcare technology for a patient-centric healthcare system.

  • Somatus-Logo

    Somatus

    Healthcare & Life Sciences

    Integrated care for patients with or at risk of developing kidney disease.

  • Cityblock Health-Logo

    Cityblock

    Healthcare & Life Sciences

    Tech-driven care provider for communities with complex needs.

  • Benchling-Logo

    Benchling

    Healthcare & Life Sciences

    Cloud based platform for research and development in biotechnology.

  • Insitro-Logo

    insitro

    Healthcare & Life Sciences

    Drug discovery and development company.

  • Weareresilience-Logo

    Resilience

    Healthcare & Life Sciences

    Operates as technology-focused biomanufacturing company dedicated to broadening access to complex medicines.

  • Lyra Healthcare-Logo

    Lyra

    Healthcare & Life Sciences

    Digital health startup using technology to connect companies and employees to mental health providers.

  • Devoted Health

    Healthcare & Life Sciences

    Provides Medicare Advantage plans to improve older Americans' well-being with comprehensive and family-oriented care.

FAQ

Questions?

We have answers

Buy Parabilis Medicines Stock

Parabilis Medicines became publicly traded following its IPO on June 10, 2026, its shares now trade on public stock exchanges under the ticker symbol PBLS. Before the IPO, Parabilis Medicines stock was privately held and available only through private market transactions.

If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.

Sell Parabilis Medicines Stock

Following its IPO on June 10, 2026, Parabilis Medicines shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.

If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.

 

Parabilis Medicines Stock Price

Following the IPO, Parabilis Medicines stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Parabilis Medicines’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.

Parabilis Medicines Stock Ticker Symbol

Following its IPO on June 10, 2026, Parabilis Medicines stock now trades on public markets under the ticker symbol PBLS. You can view real-time stock information through widely used financial data platforms.

Criteria to Sell Parabilis Medicines Stock

Following the Parabilis Medicines IPO, public shares can be sold through any brokerage.

Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

 

Criteria to Buy or Invest in Parabilis Medicines Stock

Following Parabilis Medicines’s initial public offering on June 10, 2026, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Parabilis Medicines stock can do so through their preferred broker, just as they would with any other publicly traded security.

Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

Parabilis Medicines Stock Settlement

Since Parabilis Medicines is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.

Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

Parabilis Medicines IPO

Parabilis Medicines completed its IPO on June 10, 2026, and is now publicly available through major financial sources.